765 related articles for article (PubMed ID: 14633785)
61. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
62. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
[TBL] [Abstract][Full Text] [Related]
63. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation.
Orlowski RZ
Hematology Am Soc Hematol Educ Program; 2006; ():338-47. PubMed ID: 17124081
[TBL] [Abstract][Full Text] [Related]
64. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
65. Newly diagnosed multiple myeloma.
Weber DM
Curr Treat Options Oncol; 2002 Jun; 3(3):235-45. PubMed ID: 12057069
[TBL] [Abstract][Full Text] [Related]
66. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival.
Ho PJ; Brown RD; Pelka GJ; Basten A; Gibson J; Joshua DE
Blood; 2001 Jan; 97(2):490-5. PubMed ID: 11154227
[TBL] [Abstract][Full Text] [Related]
67. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
68. Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium.
Morabito F; Recchia AG; Mazzone C; Gentile M
Curr Cancer Drug Targets; 2012 Sep; 12(7):743-56. PubMed ID: 22671929
[TBL] [Abstract][Full Text] [Related]
69. Multiple myeloma.
Bladé J; Cibeira MT; Fernández de Larrea C; Rosiñol L
Ann Oncol; 2010 Oct; 21 Suppl 7():vii313-9. PubMed ID: 20943635
[TBL] [Abstract][Full Text] [Related]
70. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
Samo AA; Li J; Zhou M; Sun Y; Yang Y; Zhang Y; Li J; van Duin M; Lu X; Fan X
Genes Chromosomes Cancer; 2018 Aug; 57(8):420-429. PubMed ID: 29696703
[TBL] [Abstract][Full Text] [Related]
71. The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma.
Bensinger WI
J Natl Compr Canc Netw; 2004 Jul; 2(4):371-8. PubMed ID: 19795599
[TBL] [Abstract][Full Text] [Related]
72. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
Tricot G; Sawyer JR; Jagannath S; Desikan KR; Siegel D; Naucke S; Mattox S; Bracy D; Munshi N; Barlogie B
J Clin Oncol; 1997 Jul; 15(7):2659-66. PubMed ID: 9215838
[TBL] [Abstract][Full Text] [Related]
73. [Molecular Mechanism and Malignant Clonal Evolution of Multiple Myeloma].
Ding F; Zhu P; Wu XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1513-6. PubMed ID: 26524068
[TBL] [Abstract][Full Text] [Related]
74. Molecular aspects of multiple myeloma.
Kastrinakis NG; Gorgoulis VG; Foukas PG; Dimopoulos MA; Kittas C
Ann Oncol; 2000 Oct; 11(10):1217-28. PubMed ID: 11106109
[TBL] [Abstract][Full Text] [Related]
75. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
Cheung WC; Van Ness B
Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
[TBL] [Abstract][Full Text] [Related]
76. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
77. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications.
Maura F; Bergsagel PL
Hematol Oncol Clin North Am; 2024 Apr; 38(2):267-279. PubMed ID: 38199896
[TBL] [Abstract][Full Text] [Related]
78. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
79. Thalidomide in the management of multiple myeloma.
Barlogie B; Tricot G; Anaissie E
Semin Oncol; 2001 Dec; 28(6):577-82. PubMed ID: 11740812
[TBL] [Abstract][Full Text] [Related]
80. Novel biologically based therapeutic strategies in myeloma.
Gupta D; Hideshima T; Anderson KC
Rev Clin Exp Hematol; 2002 Sep; 6(3):301-24. PubMed ID: 12616700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
